peginterferon-Beijing Ditan Hospital

peginterferon-Beijing Ditan Hospital refers to the therapeutic use of pegylated interferon (PEG-IFN) within clinical research frameworks established by Beijing Ditan Hospital, a leading center for liver diseases in China. The drug is a long-acting formulation of interferon alfa, modified through the covalent attachment of a polyethylene glycol (PEG) polymer. This pegylation reduces renal clearance and proteolysis, extending the half-life to allow for once-weekly subcutaneous administration. PEG-IFN acts as an agonist for the Type I interferon receptor (IFNAR), initiating the JAK-STAT signaling pathway to induce an antiviral state and enhance the host's cellular immune response. In the context of Beijing Ditan Hospital's research, it is primarily investigated for its potential to achieve a clinical cure (HBsAg seroclearance) in patients with chronic hepatitis B, including inactive HBsAg carriers and those with low-level viremia. The specific dosing of 180 mcg or 135 mcg mentioned in clinical protocols is characteristic of peginterferon alfa-2a.

Other names

peginterferonpegylated interferonpeginterferon alfa-2a